NIH-funded research NIH-funded research

Creating master cell banks for new SARS-CoV-2 vaccines

Official title: Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines

Funded at Idt Biologika Gmbh · NIH-11202800 · Data updated 2026-11-12

This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionIdt Biologika Gmbh
NIH-funded
Lab location1 site (Dessau-Rosslau, Germany)
Project startMay 15, 2018
Project endMay 14, 2028
Funding year2024
Award (this year)$1,678,100
NIH project number272201800011I-0-759302400001-2
Project IDNIH-11202800 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for participation or benefit from this research include individuals who are at risk of COVID-19 or those involved in clinical trials for new vaccines.

Less likely to help

Patients who are not at risk for COVID-19 or those who have already been vaccinated with existing vaccines may not receive direct benefits from this research.

What this research studies

This research focuses on the manufacturing and characterization of master cell banks that are essential for developing next-generation vaccines against SARS-CoV-2. It involves a comprehensive approach that includes product development planning, optimization, and compliant manufacturing processes for clinical studies. Patients may benefit from the advancements in vaccine technology that this research aims to achieve, potentially leading to more effective vaccines against COVID-19. The project also includes regulatory support to ensure that new vaccines meet safety and efficacy standards.

Why it matters

Potential benefit: If successful, this research could lead to the development of more effective vaccines against COVID-19, improving public health outcomes.

How similar studies have gone: Other research has shown success in developing vaccines using similar manufacturing and characterization approaches, indicating a promising path forward.

Where this research is happening

  • Idt Biologika Gmbh
    Dessau-Rosslau, Germany
    Active

Researchers

  • Principal investigator: Trusheim, Heidi — Idt Biologika Gmbh
  • Study coordinator: Trusheim, Heidi

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.